Pfizer – Improving the Care of Patients Living with Metastatic Breast Cancer – RFP

Well-being, Health and Biomedical Discovery


Academic Unit: Inquire within unit

Memorial Deadline: Wednesday 15th, March 2023

External Deadline: Thursday 23rd, March 2023


Please note: the original posting of this opportunity had an internal deadline of March 16, 2023. This has been adjusted to March 15th to accommodate Mid-March break.

Rethink Breast Cancer (Rethink) is known for making positive change and rethinking the status quo when it comes to breast cancer. Rethink educates, empowers and advocates for system changes to improve the experience and outcomes of those with breast cancer, focusing on historically underserved groups: people diagnosed at a younger age, those with metastatic breast cancer and people systemically marginalized due to race, income or other factors. Through collaboration, Rethink keeps the community’s voice firmly at the centre and drives impact in ways that matter most.

Beyond treatments, Pfizer works hand-in-hand with the broader cancer community to best support patients living with cancer. In this spirit, Pfizer is very proud to partner with Rethink Breast Cancer to launch this request for proposal program aimed at helping improve the lives and care of people living with breast cancer.


Date RFP Issued: January 23, 2023

Geographic Scope: Canada

Clinical Area: Oncology – metastatic breast cancer

Link to full RFP: Improving the Care of Patients Living with Metastatic Breast Cancer

Application Due Date: March 23, 2023; 11:59 pm EST

Specific Area of Interest: The intent of this RFP is to encourage proposals for the implementation of strategies that will measurably improve the quality of care of metastatic breast cancer (mBC) patients.

Topics of highlighted interest include, but are not limited to:

  • Multi-disciplinary care models (e.g., nurse navigator, palliative care, psychological/mental health support)
  • Address disparities in mBC related care for those marginalized due to age, race, income or other factors (equity, diversity, inclusion, accessibility)
  • Use real world evidence to improve quality of care for mBC
  • Strategies to encourage shared clinical-decision making between patients and their healthcare teams
  • Improved access to precision medicine and/or alternative diagnostic tools (e.g. liquid biopsy), especially considering the current COVID-19 pandemic
  • Approaches to optimize care throughout the patient cancer experience, including optimal access to clinical trials and evidence-based treatment

All submissions must include an overall “lay person’s” summary of the project proposal (please limit project summary to 5 sentences or less).

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: February 27, 2023